Safety Concern With Fingolimod to Ocrelizumab Switch in MS

A new study has suggested that some patients who make this switch may experience "double immunosuppression" – very low levels of both T and B cells, and therefore be at increased risk for infection.
Medscape Medical News

Source link

Related posts

Top 5 Confidence Building Tips for Struggling Students as They Start the New School Year


Michael Okun Talks About the Complexity and Treatment of Parkinson’s Disease


Adult and baby brains ‘sync up’ during play


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World